Beckley Psytech

Alcohol use disorder
#Alcohol Use Disorder #Beckley Psytech #Phase II trial #Psychedelics

Could a novel psychedelic treat alcohol use disorder?

A novel psychedelic compound, combined with psychological support, will be explored as a potential new treatment for people living with alcohol use disorder (AUD) in a Phase IIa study. The trial uses Beckley Psytech’s lead candidate BPL-003, a short-duration and fast-acting synthetic formulation of psychedelic mebufotenin… Read More

#News

Woman with alcohol use disorder
#Beckley Psytech #Phase II trial #Psychedelics #Substance use disorders #Synthetic biology

Phase IIa study will investigate psychedelic for alcohol use disorder

Beckley Psytech has initiated a Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD). BPL-003 is Beckley Psytech’s novel synthetic formulation of the psychedelic compound 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery… Read More

#News

Nasal spray
#Beckley Psytech #Depression #Phase II trial #Psychiatry #Treatment-resistant depression

Phase IIa study begins in treatment resistant depression

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications,… Read More

#News